Human Selenoprotein P Concentration With Glucose Tolerance Status

This study has been completed.
Sponsor:
Information provided by:
Korea University
ClinicalTrials.gov Identifier:
NCT01258426
First received: December 10, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted
  Purpose

Recently, seslenium(Se) has known as important regulator in metabolic status, lipid profile, atherosclerosis progression. SEPP1(selenoprotein P1)is a secreted protein from mainly liver. This protein is used as an index of selenium nutritional status. The association between the concentration of SEPP1(selenoprotein P1) in normal glucose tolerance,impaired glucose tolerance, type 2 diabetes is still a matter of debate. This cross sectional study will evaluate whether glucose status is matter in SEPP1 level.


Condition
SEPP1 Levels in Differnet Glucose Tolerance Status

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Human Selenoprotein P Concentration With Glucose Tolerance Status

Further study details as provided by Korea University:

Groups/Cohorts
Normal, IGT, T2DM

  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Total 180 patients Normal 60-IGT 60-T2DM 60

Criteria

Inclusion Criteria:

  • 20-80 years old
  • Not severe medical condition

Exclusion Criteria:

  • metformin, insulin using type 2 diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01258426     History of Changes
Other Study ID Numbers: SEPP1(DM)
Study First Received: December 10, 2010
Last Updated: December 10, 2010
Health Authority: Repuclic of Korea: korea Food and Drug Administration

ClinicalTrials.gov processed this record on July 28, 2014